Abiraterone
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Abiraterone: From Prostate Cancer to Migraine Disorder
One-Sentence Summary
Abiraterone is an oral inhibitor of androgen synthesis (CYP17A1) that is widely marketed in Singapore; the approved indication text is not available in the data compiled for this report. The TxGNN model predicts it may be effective for migraine disorder, but this is a computational prediction only. There are currently 0 clinical trials and 0 relevant publications supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in the registration records (no approved indication text was captured) |
| Predicted New Indication | Migraine disorder |
| TxGNN Prediction Score | 98.81% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 16 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available from the compiled sources. Based on general knowledge, abiraterone inhibits CYP17A1 and thereby suppresses androgen synthesis. It is used together with prednisone, mainly in advanced prostate cancer.
Sex-steroid fluctuation has been implicated in migraine, which is the only plausible bridge to this prediction. However, there is no evidence that CYP17A1 inhibition is therapeutic in migraine. The high TxGNN score (0.988) reflects network proximity in a knowledge graph, not clinical or experimental support.
The other top-ranked predictions are similarly unsupported. They include migraine subtypes (a genetic susceptibility phenotype and migraine with brainstem aura), leprosy, pulmonary hypertension, nephrogenic syndrome of inappropriate antidiuresis, rheumatoid arthritis, kyphoscoliotic heart disease, atrophoderma vermiculata and ulerythema ophryogenesis. None has supporting trials. The five publications retrieved under pulmonary hypertension all concern prostate cancer and appear to be retrieval mismatches rather than evidence.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for migraine disorder.
Singapore Market Information
There are 16 valid single-ingredient registrations. Approved indication text was not available for any of them. The main authorizations are:
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN15345P | ZYTIGA Film-Coated Tablet 500 mg | Film-coated tablet | Not available |
| SIN14146P | Zytiga Tablet 250 mg | Tablet | Not available |
| SIN16002P | ABIRATRED Film-Coated Tablet USP 250 mg | Film-coated tablet | Not available |
| SIN16416P | ABIRATERONE-TEVA FC Tablet 250 mg | Film-coated tablet | Not available |
| SIN17110P | Akeega Film-coated Tablets 100 mg/500 mg | Film-coated tablet | Not available |
All forms are oral (tablet or film-coated tablet).
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted hormonal therapy (CYP17A1 inhibitor), not a conventional cytotoxic |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert warnings and precautions |
| Handling Protection | Please refer to the package insert warnings and precautions |
Safety Considerations
- Drug Interactions: A screen returned 100 interacting drugs. Major-level interactions in the listed results include cisapride, dolasetron, eliglustat and loperamide. Moderate interactions include clarithromycin, levofloxacin, granisetron, metoclopramide, famotidine and several laxatives (bisacodyl, lactulose, magnesium citrate). One minor interaction is metronidazole. Several of these are QT-prolongation or CYP-related concerns and need review before any new use.
- Other safety considerations: The package insert warnings and contraindications were not available. Please refer to the package insert for them. Abiraterone is known to carry risks of hypertension, hypokalaemia and fluid retention, and it is given with a corticosteroid.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on a model score alone (L5). There are no trials, no relevant literature and no established mechanistic link between CYP17A1 inhibition and migraine. The drug's known cardiovascular and mineralocorticoid-excess adverse effects, plus long-term corticosteroid co-administration, make a non-oncology use hard to justify without evidence.
To proceed, the following is needed:
- Package insert warnings and contraindications from HSA (a blocking gap for safety screening)
- Mechanism of action data from DrugBank
- Approved indication text for the Singapore registrations
- Preclinical or mechanistic studies linking androgen or CYP17A1 pathways to migraine
- A risk-benefit assessment of long-term use in a non-cancer, likely younger and female population
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.